{"analyses":[{"ciLowerLimit":"0.88","ciNumSides":"TWO_SIDED","ciPctValue":"90.0","ciUpperLimit":"1.24","groupIds":["OG000","OG001"],"nonInferiorityComment":"The null hypothesis that atezolizumab SC is inferior to atezolizumab IV is rejected if the lower bound of the 2-sided 90% confidence interval \\[CI\\] of the geometric mean ratio is greater than or equal to (≥) the non-inferiority margin 0.8.","nonInferiorityType":"NON_INFERIORITY","paramType":"Geometric mean ratio","paramValue":"1.05"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.1","value":"85.4"},{"groupId":"OG001","spread":"127.1","value":"89.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"205"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg"},{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Per Protocol PK evaluable population included all participants randomized to the atezolizumab SC and atezolizumab IV treatment arms who did not have protocol deviations that could affect Cycle 1 observed Ctrough results.","reportingStatus":"POSTED","timeFrame":"Predose on Day 1 of Cycle 2 (Cycle length =21 days)","title":"Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1","type":"PRIMARY","unitOfMeasure":"μg/mL"}